LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP reminds investors of the upcoming May 5, 2026 deadline to file a lead plaintiff motion in the class action filed on behalf of investors ...

Nektar Therapeutics (NKTR) is up 6% during early-trading hours on Friday after the biopharmaceutical company beat fourth-quarter revenue and EPS estimates. For the fourth quarter, the company reported ...

SAN FRANCISCO (AP) — SAN FRANCISCO (AP) — Nektar Therapeutics (NKTR) on Thursday reported a loss of $36.1 million in its fourth quarter. The San Francisco-based company said it had a loss of $1.78 per ...

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Nektar Therapeutics (“Nektar” or the “Company”) (NASDAQ: NKTR) on behalf of investors concerning the ...

The sale includes discounts on the Nectar Classic Memory Foam Mattress, Nectar Luxe Hybrid Mattress and Nectar Premier Memory Foam Mattress. Nectar mattresses are popular for their comfort, cooling ...

Nektar Therapeutics is rated Strong Buy based on promising Phase 2b maintenance data for REZPEG in atopic dermatitis. REZPEG's unique mechanism expands regulatory T cells, aiming for durable immune ...

Nektar Therapeutics Inc. has established an academic research collaboration with the University of California, San Francisco (UCSF) to explore the role of tumor necrosis factor receptor 2 (TNFR2) ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The company may be one of the ...

Nektar Therapeutics (NASDAQ: NKTR) stock surged in premarket trading Wednesday after new long-term data showed its experimental eczema therapy delivered sustained and even deepening disease control ...

Nektar Therapeutics secured US$400m from an upsized follow-on that capitalised on the surge in its shares following promising Phase IIb clinical results for its eczema treatment. The biotech's stock ...

SAN FRANCISCO, Feb. 9, 2026 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR), a clinical-stage biotechnology company focused on the development of novel immunology therapies, today announced it will ...